Kathryn Chapman, a distinguished molecular bioscientist with a prolific career spanning public and private sectors, has been appointed as the new Executive Director of Innovate Cambridge. Innovate Cambridge is focused on a forward-looking innovation roadmap for the city’s tech ecosystem, recently valued at £148 billion. Chapman’s appointment comes after her significant contributions in various strategic roles including the University of Manchester, Harvard Medical School, Wellcome Trust Sanger Institute, GlaxoSmithKline, NC3Rs, and Babraham Research Campus. Her primary focus will be to amplify and support the city’s innovation system, ensuring that Cambridge continues to thrive as a global innovation hub. Under her leadership, Innovate Cambridge aims to maximize economic and social returns, fostering sustainable and inclusive growth. This new phase of growth will be highlighted at the upcoming Innovate Cambridge Summit. Key stakeholders, including Diarmuid O’Brien from the University of Cambridge and Michael Anstey from Cambridge Innovation Capital, express strong support for her role in driving groundbreaking developments and regional growth.
Innovation & Technology, Life Sciences, Private Equity & Venture Capital,United Kingdom, Cambridge
Innovate Cambridge appoints Kathryn Chapman to spearhead global ambitions